Develops treatments for newborns in the neonatal intensive care unit. Its lead candidate, TT-20, targets white matter brain injury in preterm infants and grew out of Duke research on compounds in breast milk that restore myelination.
At a glance
- Founded: 2018
- HQ: Durham
- Sector: Biotech
- Stage: Series A
- Last round: Series A
- Affiliation: Duke
Tellus Therapeutics record
Sourced from original public records. Each round and signal links to the document it was taken from.
Founders
- Jason KralicCEO and Co-founder
- Eric BennerActing CSO and Co-founder
Follow Tellus Therapeutics.
A watchlist, notes and questions on this company open with a free account.
Listed roles
All Triangle rolesChecking listed roles…